Primary Testing for Potency
Potency testing measures the active clonazepam content against labeled strength, typically using High-Performance Liquid Chromatography (HPLC). HPLC separates clonazepam from impurities by passing a sample through a column with a mobile phase, detecting peaks via UV absorbance at 254 nm. United States Pharmacopeia (USP) monograph specifies HPLC for assay, requiring 90-110% of labeled amount.[1]
Primary Testing for Purity
Purity checks for degradation products and contaminants via HPLC with impurity profiling. USP limits include clonazepam related compounds A (7-amino-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one) at ≤0.5%, and total impurities ≤1.0%. Peaks are quantified against standards.[1]
Identity Confirmation
Thin-Layer Chromatography (TLC) or Infrared (IR) spectroscopy verifies identity. TLC compares Rf values on silica gel plates with chloroform-methanol-ammonia solvent. IR matches characteristic peaks like 1700 cm⁻¹ for carbonyl.[1][2]
Dissolution and Uniformity Testing
Dissolution tests release rate in simulated gastric fluid (pH 1.2), requiring ≥80% dissolved in 30 minutes via USP Apparatus 2 (paddle).[1] Content uniformity ensures tablet-to-tablet consistency using HPLC on 10 units, with relative standard deviation ≤6%.[1]
Additional Quality Checks
- Residual Solvents: Gas Chromatography (GC) limits solvents like methanol ≤3000 ppm.[1]
- Heavy Metals: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) or colorimetry caps lead at ≤10 ppm.[2]
- Microbial Limits: Plate counts for bacteria, yeast, mold per USP <61>, <62>.[1]
- Particle Size (for powders): Laser diffraction or sieving.[2]
Manufacturers follow USP <1225> validation for these methods, ensuring accuracy, precision, and specificity. For detailed monographs, see USP-NF or DrugPatentWatch.com patent filings on analytical methods.[3]
Sources
[1]: USP Monograph: Clonazepam Tablets
[2]: ICH Q3A/B Guidelines on Impurities
[3]: DrugPatentWatch.com - Clonazepam Analytics